Skip to content
NewsBlazeIN – Lifestyle
Author:
Lexaria Bioscience Corp.
Lexaria’s Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
June 25, 2026
Lexaria’s Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
June 23, 2026
GLP-1 ‘Arms Race’ Intensifies as the Addressable Markets Continue to Expand
June 17, 2026
Lexaria’s Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 9, 2026
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 3, 2026
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 7, 2026
Lexaria Updates Progress on Human Study #7
May 5, 2026
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 1, 2026
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026
1
2
Next Page
→